These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26807318)

  • 1. The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer.
    Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Am J Cancer Res; 2015; 5(11):3376-88. PubMed ID: 26807318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signature of cytokines and angiogenic factors (CAFs) defines a clinically distinct subgroup of gastric cancer.
    Ock CY; Nam AR; Bang JH; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Gastric Cancer; 2017 Jan; 20(1):164-174. PubMed ID: 26681196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.
    Nikolinakos PG; Altorki N; Yankelevitz D; Tran HT; Yan S; Rajagopalan D; Bordogna W; Ottesen LH; Heymach JV
    Cancer Res; 2010 Mar; 70(6):2171-9. PubMed ID: 20215520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.
    Ock CY; Nam AR; Lee J; Bang JH; Lee KH; Han SW; Kim TY; Im SA; Kim TY; Bang YJ; Oh DY
    Gastric Cancer; 2017 Mar; 20(2):254-262. PubMed ID: 27147244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.
    Addison CL; Pond GR; Cochrane B; Zhao H; Chia SK; Levine MN; Clemons M
    J Bone Oncol; 2015 Jun; 4(2):47-53. PubMed ID: 26579488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of serum protein levels of angiogenic factors and their soluble receptors as markers of response to cediranib in the NCIC CTG BR.24 clinical trial.
    Addison CL; Ding K; Seymour L; Zhao H; Laurie SA; Shepherd FA; Goss GD; Bradbury PA
    Lung Cancer; 2015 Nov; 90(2):288-95. PubMed ID: 26415995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the Angiogenic Puzzle: Pre-Treatment sVEGFR1 and sVEGFR2 Levels as Promising Prognostic Indicators in Early-Stage Breast Cancer Patients.
    Zarychta E; Bielawski K; Wrzeszcz K; Rhone P; Ruszkowska-Ciastek B
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in the mRNA expression of sVEGFR1 and sVEGFR2 is associated with the selection of dominant follicle in cows.
    Ortega Serrano PV; Guzmán A; Hernández-Coronado CG; Castillo-Juárez H; Rosales-Torres AM
    Reprod Domest Anim; 2016 Dec; 51(6):985-991. PubMed ID: 27650571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Video-assisted thoracoscopic surgery lobectomy for lung cancer versus thoracotomy: a less decrease in sVEGFR2 level after surgery.
    Peng J; An S; Wang HP; Chen XL; Ning XG; Liu J; Yu XY; Mao X; Xu TR
    J Thorac Dis; 2016 Mar; 8(3):323-8. PubMed ID: 27076926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of VEGF signaling system components and matrix metalloproteinases in blood serum of gastric cancer patients.
    Gershtein ES; Korotkova EA; Petrosyan AP; Suleymanov EA; Stilidi IS; Kushlinskii NE
    Klin Lab Diagn; 2021 Nov; 66(11):650-654. PubMed ID: 34882348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of Serum Levels of IL-33, IL-37, Soluble Form of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), and Circulatory Frequency of VEGFR2-expressing Cells with Multiple Sclerosis Severity.
    Kouchaki E; Tamtaji OR; Dadgostar E; Karami M; Nikoueinejad H; Akbari H
    Iran J Allergy Asthma Immunol; 2017 Aug; 16(4):329-337. PubMed ID: 28865413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-tumor effects induced by the DNA vaccine coding human and mouse soluble VEGFR2].
    Jin L; Zhao YW; Li ZM; Zhao CJ; Wang XF; Zhang L; Yang HS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Jul; 41(4):563-6. PubMed ID: 20848769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib.
    Maitland ML; Xu CF; Cheng YC; Kistner-Griffin E; Ryan KA; Karrison TG; Das S; Torgerson D; Gamazon ER; Thomeas V; Levine MR; Wilson PA; Bing N; Liu Y; Cardon LR; Pandite LN; O'Connell JR; Cox NJ; Mitchell BD; Ratain MJ; Shuldiner AR
    Clin Cancer Res; 2015 Jan; 21(2):365-72. PubMed ID: 25411163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-Related Changes in Soluble Vascular Endothelial Growth Factor Receptor 1 (sVEGFR1) and Receptor 2 (sVEGFR2) in Healthy Japanese Subjects.
    Okamoto Y; Mita T; Kodama T; Gotoh Y; Fujita N; Fukui T; Masuzawa T
    Indian J Clin Biochem; 2015 Jul; 30(3):351-6. PubMed ID: 26089624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
    Grivas PD; Daignault S; Tagawa ST; Nanus DM; Stadler WM; Dreicer R; Kohli M; Petrylak DP; Vaughn DJ; Bylow KA; Wong SG; Sottnik JL; Keller ET; Al-Hawary M; Smith DC; Hussain M
    Cancer; 2014 Mar; 120(5):692-701. PubMed ID: 24249435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative insight in utilizing circulating angiogenic factors as biomarkers for antiangiogenic therapy: systems pharmacology approach.
    Sharan S; Woo S
    CPT Pharmacometrics Syst Pharmacol; 2014 Oct; 3(10):e139. PubMed ID: 25295574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis- and Hypoxia-Associated Proteins as Early Indicators of the Outcome in Patients with Metastatic Breast Cancer Given First-Line Bevacizumab-Based Therapy.
    Lam SW; Nota NM; Jager A; Bos MM; van den Bosch J; van der Velden AM; Portielje JE; Honkoop AH; van Tinteren H; Boven E;
    Clin Cancer Res; 2016 Apr; 22(7):1611-20. PubMed ID: 26823602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer.
    Ham IH; Oh HJ; Jin H; Bae CA; Jeon SM; Choi KS; Son SY; Han SU; Brekken RA; Lee D; Hur H
    Mol Cancer; 2019 Mar; 18(1):68. PubMed ID: 30927911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of pretreatment serum levels of VEGF and its receptors, IL- 8, and their prognostic value in type I and II endometrial cancer patients.
    Kotowicz B; Fuksiewicz M; Jonska-Gmyrek J; Berezowska A; Radziszewski J; Bidzinski M; Kowalska M
    PLoS One; 2017; 12(10):e0184576. PubMed ID: 28991928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer.
    Liu X; Xu P; Qiu H; Liu J; Chen S; Xu D; Li W; Zhan Y; Li Y; Chen Y; Zhou Z; Sun X
    Onco Targets Ther; 2016; 9():949-58. PubMed ID: 27013889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.